Skip to main content

The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making

Buy Article:

$63.00 plus tax (Refund Policy)

Lung cancer is the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC), accounting for about 85% of all lung cancers, includes squamous carcinoma, adenocarcinoma and undifferentiated large cell carcinoma. The majority of patients have advanced disease at diagnosis, and medical treatment is the cornerstone of management. Several randomized trials comparing third-generation platinum-based doublets concluded that all such combinations are comparable in their clinical efficacy, failing to document a difference based on histology. However, recent evidences, arising from the availability of pemetrexed, have shown that histology represents an important variable in the decision making. The major progresses in the understanding cancer biology and mechanism of oncogenesis have allowed the development of several potential molecular targets for cancer treatment such as vascular growth factor and its receptors and epidermal growth factor receptor. Targeted drugs seem to be safer or more effective in a specific histology subtype. All of these data have led to choose the optimal first-line treatment of advanced NSCLC based on histologic diagnosis. However, this scenario raises a diagnostic issue: a specific diagnosis of NSCLC histologic subtype is mandatory.

This review will discuss these new evidences in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: NSCLC; bevacizumab; chemotherapy; figitumumab; first-line therapy; histology-based therapy; pemetrexed; sorafenib

Document Type: Research Article

Affiliations: Division of Medical Oncology,“S.G. Moscati” Hospital, Contrada Amoretta, 8, 83100 - Avellino,Italy.

Publication date: 2010-04-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more